The University of Southern California’s Keck School of Medicine is recruiting patients for a Phase 1 clinical trial evaluating RNDP-001, an experimental cell replacement therapy being developed by Kenai Therapeutics for moderate to severe Parkinson’s disease. The company-sponsored REPLACE (NCT07106021), which began dosing late last year,…
